web analytics
15.8 C
Munich
Saturday, July 24, 2021

Rushnet Inc (OTCMKTS: RSHN) Rising Bull: RM heliosDX Record Numbers, LOI to Acquire Lab with Colossal Sales

Rushnet Inc (OTCMKTS: RSHN) is a sleeping that is making a powerhouse run up the charts in recent days as the Company drops big on its recently acquired by Ashley Sweat. So far, 2nd Quarter is proving to be yet another record quarter for heliosDX. In the 1st Quarter of 2021, heliosDX generated a record $1,252,000 in revenue. This was a new company benchmark. In April and May 2021, heliosDX has generated revenues totaling approximately $990,000 respectively. This is an average of $495,000 a month. This also includes another record of approximately $530,000 in revenue for the month of May. This growth puts heliosdDX on pace to hit their stretch projected 2nd quarter target of $1.4 to $1.5 million. This again sets another company benchmark. This would equate to just over a 20% revenue growth quarter over quarter. heliosDX enjoyed a 70%+ revenue growth from 2019 to 2020, and to see the growth continue speaks volumes to the execution of the plan, and the staff at heliosDX. 

Rushnet Inc has been around for years selling edibles and beverage based company with stand-alone products, including most enhanced with CBD. Recentlly they aquired HeliosDx and Chattahoochee Labs which has been around since 2006 and has generated well over 6 million dollars in revenue in 2021.This year we take on our third mass spectrometer, the powerful Absciex 4500, which will allow us to serve the massive needs of our clientele, which has been under strain.With the procurementof a new QuantStudio 12x we now have the ability to test 1500 Covid19 patients per day. With infectious disease testing validations being completed next week, we will be able to better serve clients all over by creating more robust testing menus and quicker turnaround time for Covid19, UTI, and RPP testing. Furthermore, with the assumption of our Ion S5 GeneStudio NGS testing equipment, we are poised for the huge genetics market that is so underserved 

heliosDX has had a delay in launching their Infectious Disease platform in-house. However, heliosDX does continue to realize revenue from this platform by referencing out tests. That said, the original revenue growth target for Q2 included revenue from launching infectious disease as an in-house testing platform. The good news, heliosDX will still achieve our quarter 2 revenue targets. In addition, we are about a week out from launching the platform in-house realizing even more revenue and testing volume growth. There has been a change in the verbiage from RushNet, Inc acquiring heliosDX, to RushNet, Inc being acquired by Ashley Sweat. Ashley Sweat currently serves as the Chairman and CEO of RushNet. Inc. He also is the Owner and CEO of heliosDX. The plan has been and continues to be to reverse merge heliosDX into RushNet, Inc. As mentioned previously, this is a very fluid process, and thus there have been structural changes to the Purchase Agreement to ensure long-term success of this transaction, and the company in general moving forward. 

Some key events being worked on by the Company include: Filing Disclosures Imminent, Filing Financials Imminent, Attorney Letter Coming, Mid Quarter Financial update and Highlights Released. Pink Current Coming, Audit Financials In Process, Website transition chattahoocheelabs.com to heliosDX.com – Near Completion, Professional Sales and Marketing Video In Progress. Spin Off RushNet, Inc Subsidiaries, Acquisition(s) and/or LOI Update, Complete the Reverse Merger, R/S Reassessment, Reengage FINRA. SEC Reporting 

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

On June 7, Rushent with merger/acquisition target heliosDX, sighned a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. The acquisition further increases the National footprint of heliosDX while also reducing costs, tripling the sales force, and increasing the capacity to process substantially more testing in the UDS portfolio. Significantly, the types of tests offered by heliosDX coupled with those offered by the new facility create a more expansive combined testing capacity. It is apparent as the market continues to evolve, weshould attain an even higher sales volume and footprint to secure larger national contracts, particularly with insurance carriers and medical groups, which is critical to the long-term success of heliosDX. The acquisition would expedite this process along with offering more testing options at the target labs clinic sites which are not presently available, including PCR, Allergy and PGx. Conversely, the target laboratory will expand heliosDX testing capabilities and portfolio with Oral Fluid Toxicology. 

Management has been working hard behind the scenes recently filing of the Attorney Letter with respect to periods ending Dec 31, 2019, and 2020 all requirements have been satisfied to become Pink Current. In the coming days, the company should move to a Yield Sign due requirements being satisfied. At that time, OTCMarkets will conduct their review of the recent filings, and we expect the company to move Pink Current. RSHN management has also made is clear there is no Reverse split coming during the upcoming transactions. 

We have a Monster Pick Coming. Subscribe Right Now!

RSHN is a sleeping that is making a powerhouse run up the charts in recent days as the Company drops big on its recently acquired by Ashley Sweat. So far, 2nd Quarter is proving to be yet another record quarter for heliosDX. In the 1st Quarter of 2021, heliosDX generated a record $1,252,000 in revenue. This was a new company benchmark. In April and May 2021, heliosDX has generated revenues totaling approximately $990,000 respectively. This is an average of $495,000 a month. This also includes another record of approximately $530,000 in revenue for the month of May. This growth puts heliosdDX on pace to hit their stretch projected 2nd quarter target of $1.4 to $1.5 million. This again sets another company benchmark. This would equate to just over a 20% revenue growth quarter over quarter. heliosDX enjoyed a 70%+ revenue growth from 2019 to 2020, and to see the growth continue speaks volumes to the execution of the plan, and the staff at heliosDX. On June 7, Rushent with merger/acquisition target heliosDX, sighned a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. The acquisition further increases the National footprint of heliosDX while also reducing costs, tripling the sales force, and increasing the capacity to process substantially more testing in the UDS portfolio. Significantly, the types of tests offered by heliosDX coupled with those offered by the new facility create a more expansive combined testing capacity. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RSHN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.